Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydrocodone controlled-release - Purdue Pharma

Next Previous
X
Search
Drug Profile

Hydrocodone controlled-release - Purdue Pharma

Alternative Names: HYD - Purdue Pharma; hydrocodone bitartrate extended-release - Purdue Pharma; Hydrocodone bitartrate once-daily - Purdue Pharma; Hysingla

Latest Information Update: 08 Jan 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Purdue Pharma
  • Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 21 Apr 2017 Purdue Pharma withdraws prior to enrolment its phase II trial for Pain (In adolescents) in USA (NCT02542098)
  • 08 Sep 2015 Purdue Pharma plans a phase II trial for Pain (In adolescents) in USA (NCT02542098)
  • 13 May 2015 Adverse events data from a phase III trial in Pain presented at the 34th Annual American Pain Society Scientific Meeting (APS-2015)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top